AbstractBySubCategory

Prostate Cancer - Advanced Disease

Genitourinary Cancer

2017 Genitourinary Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
The long tail of significantly mutated genes in prostate cancer. Joshua Armenia

131

Clinical significance of AR mRNA quantification from circulating tumor cells (CTCs) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (Abi) or enzalutamide (Enza). John Silberstein

132

Individual patient level meta-analysis of the performance of the Decipher genomic classifier in high-risk men post-prostatectomy to predict development of metastatic disease. Daniel Eidelberg Spratt

133

AR nuclear localization and microtubule bundling as markers of docetaxel and cabazitaxel sensitivity in metastatic castration-resistant prostate cancer (mCRPC): Prospective biomarker analysis from TAXYNERGY. Paraskevi Giannakakou

134

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC. Michael Paul Kolinsky

135

Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel. Gwenaelle Gravis

136

Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D). Lauren Christine Harshman

137

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial. Andrew J. Armstrong

138

Single cell phenogenomic subtyping of circulating tumor cells (CTCs) identify intercellular tumor heterogeneity (het) and multiple resistance mechansisms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Howard I. Scher

139

Germline DNA repair mutations in metastatic castration-resistant prostate cancer: Therapy response and applicability of circulating tumor DNA. Werner J. Struss

140

Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial. Joaquin Mateo

141

Genomic classifier to augment the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model. Firas Abdollah

142

Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC). Lawrence Fong

143

Rapid, ultra-low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy in metastatic castration-resistant prostate cancer (mCRPC). Daniel H. Hovelson

144

Genetic polymorphisms to predict progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone therapy: Results from the NCI 9012 trial. Costantine Albany

145

PACIFIC trial: A randomized phase II study of apatorsen and abiraterone in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) who have had PSA progression while receiving abiraterone (ABI). Kim N. Chi

146

Seizure rates in enzalutamide (ENZ)-treated men with metastatic castration-resistant prostate cancer (mCRPC) at increased risk of seizure: UPWARD study. Susan F. Slovin

147

Whole-exome sequencing of single circulating tumor cells is a useful tool for studying the intrapatient genetic heterogeneity in metastatic prostate cancer. Vincent Faugeroux

148

Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. Guru Sonpavde

149

Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review. Maxine Sun

150

Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC). Phillip Lee Palmbos

151

Circulating tumor cells (CTCs) and plasma cell free DNA (cfDNA) androgen receptor amplification (ARamp)-based prognosis in metastatic castration-resistant prostate cancer (mCRPC). Manish Kohli

152

Estimating the incidence of oligorecurrent and potentially salvageable prostate cancer on 18F-Choline PET-CT: Screening phase of the STOMP randomized phase II trial. Piet Ost

153

Effects of radium-223 (Ra-223) with docetaxel versus docetaxel alone on bone biomarkers in patients with bone-metastatic castration-resistant prostate cancer (CRPC): A phase I/IIa clinical trial. Michael J. Morris

154

Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study. Kambiz Rahbar

155

First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset. Guru Sonpavde

156

Aberrant tumor metabolism to enable glucocorticoid receptor takeover in enzalutamide-resistant prostate cancer. Nima Sharifi

157

Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP). Axel Heidenreich

158

Avelumab in metastatic castration-resistant prostate cancer (mCRPC). Farhad Fakhrejahani

159

Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide. Vincenza Conteduca

160

Indomethacin to inhibit AKR1C3 intracrine androgen production and sensitizes prostate cancer (PCa) to enzalutamide. Chong-xian Pan

161

A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC). Fatima Karzai

162

Multisite experience of fluciclovine (18F) PET/CT imaging in biochemically recurrent prostate cancer: Impact of clinical factors and intersite variation. Lucia Zanoni

163

Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis. Firas Abdollah

164

Efficacy and safety of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone acetate (Abi): A multicenter, single-arm, open-label study. Johann S. De Bono

165

A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. Esther W. Bouman-Wammes

166

Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC). Tanya B. Dorff

167

A novel small molecule inhibitor of p300/CBP for the treatment of castration-resistant prostate cancer: Preclinical evaluation. Nigel Brooks

168

Cabozantinib plus androgen deprivation therapy in patients with androgen-dependent metastatic prostate cancer. Paul Gettys Corn

169

Translating Prostate Cancer Working Group 2 (PCWG2) progression criteria into a quantitative response biomarker in metastatic castration-resistant prostate cancer (mCRPC). Aseem Anand

170

Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis. Helgstrand Thomas John

171

Independent validation of effect of HSD3B1 genotype on response to androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer (HSPC). Andrew W. Hahn

172

Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy. Edwin M. Posadas

173

Polymorphisms of the androgen transporting gene SLCO2B1 and response to abiraterone acetate in mCRPC patients. Silvana Giacinti

174

Association of Wnt pathway activation with prechemotherapy abiraterone acetate resistance in metastatic castration-resistant prostate cancer (mCRPC) by genome-wide analysis of metastases. Manish Kohli

175

A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC). Russell Zelig Szmulewitz

176

Relationship between quality of life and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients in ALSYMPCA. Sten Nilsson

177

Association of PET index quantifying skeletal uptake in NaF PET/CT images with overall survival in prostate cancer patients. Sarah Lindgren Belal

178

A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa). Deepak Kilari

179

Evidence of linkage in MSH6-associated region exclusive to high-risk African-American families with prostate cancer. Elisa M. Ledet

180

Impact of metformin on prostate cancer (PC) outcomes in the E3805 CHAARTED trial. David Frazier Jarrard

181

Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Mark Christopher Markowski

183

Therapeutic targeting of tumor-associated macrophages through microscale engineering of the prostate cancer microenvironment. David Kosoff

184

Inherited pathologic mutations and family history in patients with prostate cancer. Shuwen Lin

185

Circulating tumor DNA (ctDNA) and correlations with clinical prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC). Daniel Khalaf

186

Evaluation of a multimodal strategy to accelerate drug evaluations in early-stage metastatic prostate cancer. Matthew O'Shaughnessy

187

A drug-drug interaction study on the combination of cabazitaxel with enzalutamide in patients with metastatic castration-resistant prostate cancer. Bodine P.S. Belderbos

188

Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer. Emma Carroll

189

Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts). Eric Jay Small

190

AR-V7 detection by a novel junction-specific RNA in situ hybridization (RISH) test. Yezi Zhu

191

Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T). David I. Quinn

192

Clinical versus radiographic progression and overall survival for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from COU-AA-302. Charles J. Ryan

193

Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) to prognosticate overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi). David Wise

194

Race, demographics, and socioeconomics as they relate to newly diagnosed metastatic prostate cancer in the United States. Richard Matulewicz

195

Boosting long-term immune responses to sipuleucel-T (sip-T) by retreatment of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Tomasz M. Beer

196

The impact of TAS3681, a new type of androgen receptor antagonist, on aberrant AR signaling that drives tumor resistance to AR-targeted therapies by down-regulating full length and splice variant AR. Daisuke Kajiwara

197

Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Amandeep R. Mahal

198

The Prostate Cancer Project (PC Project): Translational genomics through direct patient engagement. Stephanie Anne Mullane

199

Genomic analysis of untreated prostate adenocarcinoma, treatment-emergent neuroendocrine carcinoma, and circulating tumor cells. David James VanderWeele

200

Taste and prostate cancer: Preliminary data on a novel patient-reported outcomes. Lydia D. Chow

201

Preclinical discovery and validation of high-dose androgen drug synergies for the treatment of prostate cancer. Michael D. Nyquist

202

A phase II study combining ipilimumab and degarelix with or without radical prostatectomy (RP) in men with newly diagnosed metastatic noncastration prostate cancer (mNCPC) or biochemically recurrent (BR) NCPC. Karen A. Autio

203

Targeting reciprocal feedback inhibition: Apalutamide and everolimus in patients with metastatic castration-resistant prostate cancer (mCRPC). Dana E. Rathkopf

204

Studies of a novel modified E2F-targeted peptide with activity against castration-resistant prostate cancer. Joseph R. Bertino

205

Immune evaluation study of sipuleucel-T (Sip-T) in African-American and European-American men with castration-resistant prostate cancer. Archana Thakur

206

The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer. Zachary A Glaser

207

Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair. Maryam Ghashghaei

208

High-resolution peripheral quantitative computed tomography (HR-pQCT) to detect compartmental bone loss on androgen deprivation therapy (ADT): A feasibility study. Rahul Raj Aggarwal

209

A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer. Steven Yu

210

Racial and age specific differences in localized and metastatic prostate cancer incidence: 1988-2013. Marc Dall'Era

211

Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The prostate cancer registry. Simon Chowdhury

212

Prostate-specific membrane antigen (PSMA) PET-CT guided radiotherapy in oligometastatic prostate cancer. Benedikt Engels

213

Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices. William K. Oh

214

Evaluation of treatment patterns and costs for patients with prostate cancer and bone metastases. Adriana Valdarrama

215

Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry. Andrew J. Armstrong

216

Diagnostic characteristics of men harboring lethal prostate cancer: A population-based analysis. Helgstrand Thomas John

217

Patient expectations from systemic treatment of metastatic prostate cancer (mPC). Kelvin A. Moses

218

Exploring optimal sequence of abiraterone and enzalutamide in patients with castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. Naoki Terada

219

Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naïve prostate cancer (HNPC): 3-year, open-label, follow-up results. Bertrand F. Tombal

220

Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database. Edoardo Francini

221

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer. Przemyslaw Twardowski

222

Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer. Tanya B. Dorff

223

Contribution of mouse adrenal glands to intratumor androgens and growth of castration-resistant prostate cancer xenografts. Elahe A. Mostaghel

224

Family history, race, and prostate cancer. Joshua Schiff

225

Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors. Sherri Z. Millis

226

Predictors of long-term response to abiraterone acetate with prednisone and cabazitaxel after first-line docetaxel in patients with metastastic castration-resistant prostate cancer (mCRPC): Subgroup analysis of a prospective observational study. Nuria Sala

227

Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). Austin Poole

228

Accuracy of 68Ga-PSMA-PET/CT for patient selection for lymphadenectomy in addition to salvage radical prostatectomy in locally recurrent prostate cancer after primary radiotherapy. David Pfister

229

Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in pts with metastatic castration-resistant prostate cancer (mCRPC) receiving a new agent (NA)- based third-line treatment: Final results from a multicenter Italian study. Orazio Caffo

230

Imaging metastatic prostate cancer with 18F-DCFBC PET/CT (DCFBC) and 18F-NaF PET/CT (NaF). Farhad Fakhrejahani

231

Investigating RUNX1 and RUNX2 in prostate cancer. Anne Jane McKillop

232

Treatment sequencing of abiraterone and enzalutamide in patients with mCRPC. Allison H. Feibus

233

Association of cfDNA androgen receptor amplifications with BRAF alterations in mCRPC. Elisa M. Ledet

234

Risk factors for metastatic prostate cancer: A sentinel event case series. Channing Judith Paller

235

Tissue-based analytics provide the next generation of prostate cancer risk models. Michael Donovan

236

A personalized medicine approach to identifying dysregulated epigenetic enzymes in the development of castrate-resistant prostate cancer. David Frazier Jarrard

237

Assessment of urologists experience with abiraterone acetate and with a real-world trial: Results obtained from a Canadian Observational Study in Metastatic Cancer of the Prostate (COSMiC). Andrew Feifer

238

Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). Martin Boegemann

239

Clinical activity and safety of ASN001, a selective CYP17 lyase inhibitor, administered without prednisone in men with metastatic castration-resistant prostate cancer (mCRPC). Jorge A. Garcia

240

The role of cytoreductive radical prostatectomy (cRP) in men with hormone-sensitive, metastatic prostate cancer (mPCA). Axel Heidenreich

241

Charlson Score as prognostic factor in patients with castration-resistant prostate cancer. Gustavo Jankilevich

242

Telemedicine-enabled clinical trial of metformin in patients (pts) with biochemically-recurrent prostate cancer (PCa). Matt D. Galsky

243

Impact of income in stage IV prostate cancer. Aabra Ahmed

244

Eligibility criteria requirements and adherence in advanced prostate cancer trials. Sarah Wong

245

ODM-204 a novel dual inhibitor of CYP17A1 and androgen receptor: Early results from phase I dose escalation in men with castration-resistant prostate cancer. Karim Fizazi

246

Novel biomarker of specific castration-resistant prostate cancer (CRPC) by exploring the proteome analysis. Hiroji Uemura

247

A phase II study of muscadine grape skin extract in men with biochemically recurrent prostate cancer. Channing Judith Paller

248

Patient NCCN risk classification based on combined clinical cell cycle risk (CCR) score. Steven Stone

249

Liver metastases in mCRPC patients post-therapy with abiraterone (Abi) and/or abiraterone/enzalutamide (Enza). Lahiru Ranasinghe

250

AR amplification eradication with high-dose testosterone (T) in patients with heavily pretreated mCRPC. Patrick Cotogno

251

Population-based analysis of treatment toxicity among men with castration-resistant prostate cancer. Robert Nam

252

Impact of circulating tumor cell (CTC) nucleus size on outcomes with abiraterone acetate (AA) therapy in men with metastatic castration-resistant prostate cancer (mCRPC). David Michael Gill

253

Patients with metastatic castration-resistant prostate cancer (mCRPC) who are long-term responders (LTR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA. Orazio Caffo

254

Short- and long-term outcomes of salvage lymph node dissection in patients with clinically recurrent prostate cancer. Giorgio Gandaglia

255

Validation of the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer (CRPC): Data from TRUMPET. Scott Flanders

256

National, centralised hospital datasets can inform clinical trial outcomes in prostate cancer: A pilot study in the STAMPEDE trial. Harriet Paige Mintz

257

Survival outcomes for de novo versus primary progressive metastatic prostate cancer. Kanika Gupta

258

An update on clinical outcome data for a phase II randomized study comparing androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in men with locally advanced/metastatic hormone sensitive prostate cancer. Adam Hassani

259

Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer. Nedal Bukhari

260

Efficacy of eplerenone (Epe) in the management of mineralocorticoid excess (MCE) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (AA) without prednisone (P). David Michael Gill

261

Histone demethylase KDM7a to control androgen receptor activity in hormone-sensitive prostate cancer. Minyong Kang

262

Stereotactic body radiotherapy for patients with relapsing prostate cancer with bones or nodes oligometastases. Pierre-Antoine Laurent

263

Challenges in enrolling to metastatic castration-resistant prostate cancer (mCRPC) studies that require androgen receptor splice variant (AR-V) positivity. Michael Thomas Schweizer

264

Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC). David Michael Gill

265

A video-based, personalized web page (VBPWP) as a complement to clinical trial (CT) patient management. Hannah Mills

266

Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database. Nicolas Delanoy

267

Long-term androgen deprivation therapy (ADT) with leuprorelin and quality of life in patients with advanced prostate cancer (PCa). Peter Hammerer

268

Statin inhibits the proliferation of human castration-resistant prostate cancer cells by controlling NFkB-LIN28B-let7 miRNA signaling pathway. Minyong Kang

269

Concordance in the relative mortality rates for prostate cancer and gastric cancer in African Americans. John Clark Henegan

270

De novo metastatic prostate cancer: Patterns of PSA testing prediagnosis and disease characteristics. Yasser Ged

271

Characterization of cancer family history among patients with PCa cancer. Emma M. Ernst

272

An oral androgen receptor PROTAC degrader for prostate cancer. Taavi K Neklesa

273

Efficacy of additional chemotherapy following failure of currently approved therapies in patients with castration-resistant prostate cancer. Luca Campedel

274

Modes of action of low-dose cabazitaxel in combination with the antiangiogenic and antitumoral pigment epithelium-derived factor in prostate cancer. Thomas Nelius

275

Abiraterone acetate with prednisone and cabazitaxel as subsequent treatment after first-line docetaxel in metastatic castrate-resistant prostate cancer (mCRPC): Final efficacy and safety analysis of the CAPRO study. Arancha Gonzalez del Alba

276

The usefullness of low-molecular-weight protein tyrosine phosphatase as a prognostic factor in metastatic hormone-sensitive prostate cancer. Mari Ohtaka

277

The natural history, treatment, and survival of 199 patients with sarcomatoid carcinoma of the prostate. Sreeja Biswas Roy

278

Expression of somatostatin receptor subtypes, aurora kinase A, and interleukin-6 in prostate cancer before androgen ablation. Angela Gernone

e564

MILGa-01: A first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers. Howard Gurney

e565

Evaluation of cabazitaxel's toxicity and tolerance: AC Camargo Cancer Center experience. Christiane Silveira Marinho Albuquerque

e566

Predictive factors and the important role of detectable prostatic specific antigen for the detection of clinical recurrence following robot-assisted radical prostatectomy. Silvia Garcia Barreras

e567

Questionnaire to evaluate prostate cancer multidisciplinary committees in Spain. Javier Cassinello

e568

Impact of pharmacist-led monitoring of olaparib (O) for metastatic castrate resistant prostate cancer (mCRPC). Andrea McNatty

e569

Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide. Mi Hwa Heo

e570

Heterogeneous populations driven by clinical practice: A case example comparing enzalutamide (ENZA) and bicalutamide (BIC). Ruth Kim

e571

Refill gaps and dose reductions in patients treated with abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ). Dominic Pilon

e572

Real life treatment sequences and survival of men with metastatic castrate-resistant prostate cancer (mCRPC) receiving cabazitaxel in clinical practice across England. Alison J. Birtle

e573

Early assessment of PSA response in patients with mCRPC treated with enzalutamide and abiraterone. Allison H. Feibus

e574

Predictors of response to platinum (Pt)-based chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). Deepak Kilari

e575

Association between primary surgery and all-cause mortality among elderly patients with high-risk prostate cancer. Sumedha Chhatre

e576

A probabilistic threshold analysis of metformin (Met) with enzalutamide (Enza) to determine the cost and added efficacy needed to make such a combination theray cost-effective (CE). Jordan Hill

e577

Interim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate cancer. Bertram E. Yuh

e578

3D-microdevice for the in vivo capture of cancer-associated circulating cells. Hélène Cayron

e579

Physiological evidence of DNA damage by carcinogens known to be present in charred and processed meats (PhIP DNA adducts) in a small cohort of patients with prostate cancer. Christopher J. Weight

e580

Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer. Sandra Assoun

e581

Platelets harbor prostate cancer biomarkers and the ability to predict therapeutic response in castration-resistant patients. Camilla Thellenberg Karlsson

e583

Cell-free DNA as a surrogate marker in patients with CRPCA undergoing taxane-based chemotherapy. Friederike Haidl

e584

Patients with metastatic castration-resistant prostate cancer (mCRPC) are primary resistant (PR) to the new agent (NA)-based second line: Clinical outcomes and prognostic factors of subsequent treatment with another NA. Orazio Caffo

e585

Polymer-delivered, subcutaneously administered leuprolide acetate provides consistent and prolonged drug delivery in castrate men with advanced prostate cancer. Lane Childs

e586

Prevalence of oligoprogressive, metastatic castration-resistant prostate cancer (mCRPC) amenable to stereotactic ablative radiotherapy (SABR) in men undergoing abiraterone acetate (AA) therapy. Erica McDonald

e587

A multivariate index analyte (MIA) assay for differentiating aggressive from nonaggressive prostate cancer. Douglas Campbell

e588

Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients. Judd W. Moul

e589

Serial FDG-PET imaging of metastatic prostate cancers reveals intrapatient intermetastases polyclonality through same patient heterogeneous responses to systemic therapy. Fannie Morin

e590

Is there an additional benefit of Tc-99m-PSMA-guided gamma probe use for salvage lymph node dissection in recurrent prostate cancer. David Pfister

e591

Polymer delivered, subcutaneously administered leuprolide acetate provides stable and long-term drug delivery and testosterone suppression in 4 pivotal trials. Franklin Chu

e592

Evaluating the effect of therapy duration on survival in patients with metastatic castration-resistant prostate cancer receiving radium-223. Noelle L. Williams

e593

Radium-223 in metastatic castration-resistant prostate cancer: Effect of performance score and albumin levels. Amarnath Challapalli

e594

The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy. Pengfei Shen

e595

Evaluation of bone metastasis of castration-resistant prostate cancer after enzalutamide and abiraterone using Bone Scan Index on bone scintigraphy. Suguru Kadomoto

e596

Prognostic factors for overall survival in patients with metastatic castration-resistant prostate cancer: Secondary analysis. Andrea Carolina Anampa-Guzman

e597

Does Gleason pattern 5 influence the efficacy of enzalutamide against castration-resistant prostate cancer? Tatsuya Shimomura

e598

Changes in hormonal therapy during the first 24 months of treatment: A longitudinal cohort study. Thierry Lebret

e599

Effect of chemotherapy on survival for intraductal carcinoma of the prostate (IDC-P) in patients with castration-resistant prostate cancer. Akiyuki Yamamoto

e601

Predictors for survival with cabazitaxel (CBZ) in metastatic, castration-resistant prostate cancer (mCRPC): Long term follow-up of the Spanish registry. Iria González-Maeso

e602

The prognostic role of IDC-P in mCRPC and its predictive value in those treated with docetaxel or abiraterone as first-line therapy. Jinge Zhao

e603

Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy. Yoshifumi Kadono

e604

Single-dose, four-way crossover, open-label, relative bioavailability (BA) studies of a novel formulation of abiraterone acetate (AA) versus the reference formulation under fasted conditions in healthy male subjects. Ronald Goldwater

e605

Absorption of a novel formulation of abiraterone acetate (AA) fine particle (AAFP) under fed and fasted conditions. Alexander Papangelou

e606